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Histamine H1 receptor (H1R) antagonists, or antihistamines, are often used for 
treatment of allergic disorders such as seasonal rhinitis.  Antihistamines mainly act on the 
peripheral tissues but can induce sedation.  This undesirable central side effect is caused 
by blockade of nerve transmission in the histaminergic neuron system which projects from 
the tuberomammillary nucleus in the posterior hypothalamus to almost all cortical areas1-3).  
First-generation antihistamines, such as diphenhydramine and d-chlorpheniramine, that can 
easily penetrate blood-brain barrier (BBB) tend to occupy a large proportion of 
post-synaptic H1Rs4-6).  Second-generation antihistamines, such as fexofenadine, cetirizine 
and olopatadine, can slightly penetrate BBB and H1Rs are slightly occupied as having been 
demonstrated using positron emission tomography (PET)4,7-9).  Variation in cerebral H1R 
occupancy (H1RO) of antihistamines results mainly from their different BBB permeability. 
Thus, sedative property of antihistamines can be evaluated in terms of H1RO measured 
with PET and [11C]doxepin, a radiopharmaceutical that specifically binds to H1Rs.  
 
Methods 
The present study was approved by the Committee on Clinical Investigation at 
Tohoku University Graduate School of Medicine, Japan, and was performed in accordance 
with the policy of the Declaration of Helsinki.  All experiments were performed at the 
Cyclotron and Radioisotope Centre, Tohoku University.  Eight healthy male volunteers 
(mean age +/- s.d.: 24.4 +/- 3.3 years old) were studied after single oral administration of 
bepotastine 10 mg, diphenhydramine 30 mg or placebo, using PET with [11C]doxepin in a 
crossover study-design.  Binding potential ratio and H1R occupancy values were 
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calculated using placebo data, and were compared between bepotastine and 
diphenhydramine.  PET brain images, after being corrected for tissue attenuation, were 
reconstructed with a filtered back projection algorithm.  The brain images were then 
normalized by plasma radioactivity at 10 min post-injection to yield static distribution 
volume (DV) images according to our static scan protocol reported previously10). 
For visualization at a whole-brain level, DV brain images were analyzed statistically on a 
voxel-by-voxel basis by Statistical Parametric Mapping (SPM2).  Differences in parameter 
values between bepotastine, diphenhydramine and placebo (control) were statistically 
examined, and regional maxima of statistical significance (p< 0.001) were projected onto 
the surface-rendered MRI-T1 standard brain images.  
 
Results 
Brain images following administration of bepotastine demonstrated slightly lower 
binding potential in comparison to those following placebo, and images following 
diphenhydramine administration demonstrated significantly lower binding potential in 
comparison to both placebo and bepotastine (Figure 1).  Using SPM2 on a voxel-by-voxel 
basis, parametric brain BPR images following treatment with bepotastine or 
diphenhydramine were statistically compared to those following treatment with placebo. 
Areas such as ACC, MPFC and DLPFC, TC demonstrated significantly low BPRs after 
treatment with diphenhydramine as compared to treatment with placebo.  On the other 
hand, SPM analysis did not reveal any brain area where BPRs were significantly lower 
following treatment with bepotastine than following treatment with placebo.  Overall 
cortical mean H1RO of bepotastine and diphenhydramine were 14.8% and 56.8%, 
respectively.  H1R occupancy of both bepotastine and diphenhydramine correlated well 
with their respective drug plasma concentration (p< 0.001).  
 
Discussion 
Human molecular imaging, especially a non-invasive imaging of biological 
phenomena at a molecular level in living human brain, has been actively conducted.  In 
the present study, H1RO of bepotastine, a second-generation antihistamine, was compared 
to that of diphenhydramine, a typical sedative antihistamine, in a single-blinded 
placebo-controlled crossover study-design.  H1RO after a single oral administration of 
bepotastine 10 mg or diphenhydramine 30 mg was calculated as approximately 14.8% and 
56.8%, respectively.  It has also been reported that, single-oral administration of 
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d-chlorpheniramine (2 mg) achieved approximately 50 to 77% of H1RO4,8).  As a whole, 
previous PET studies demonstrated that first-generation antihistamines occupied more than 
50% of available H1Rs.  
On the other hand, H1RO after single-oral administration of bepotastine (5 mg) was 
much lower than that of first-generation antihistamines (15% vs. 50%).  This result is in 
accordance with the categorization of bepotastine as a second-generation antihistamine. 
Previous studies have demonstrated H1ROs due to other second-generation antihistamines: 
epinastine 20 mg (8.2 to 13.2%)5,6), terfenadine 60 mg (12.1-17.1%)4,6), astemizole 10 mg 
(28.7%), azelastine 1 mg (20.3%), mequitazine 3 mg (22.2%)6) and ebastine 10 mg (9.9%)6).  
As a whole, second-generation antihistamines would occupy around 0 to 20% of brain 
H1Rs6).  Later, single-oral doses of cetirizine 20 mg and fexofenadine 120 mg, both 
double oral doses in Japan, were reported to achieve 26% and 0%, respectively6).  Based 
on such findings, second-generation antihistamines can be further separated into two 
subgroups according to their BBB permeability2,3); a category that cause little sedation at 
low doses, but cause dose-related cognitive impairment at higher doses as seen with 
cetirizine, and the other category that does not cross BBB and therefore induces no sedation 
even at exceeded doses as seen with fexofenadine9).  
The reasons for the small number of placebo-controlled crossover studies would be 
their disadvantages such as increased radiological exposure to subjects as the same subject 
is scanned more than twice.  Investigators are therefore advised to minimize total radiation 
exposure to subjects by choosing a minimum radiological dose and by using 3D data 
acquisition mode with high sensitivity.  In addition, mental and physical stress of the 
subjects should be reduced by simplifying measurement protocol, as in the present study 
where complete dataset were obtained for all of the eight subjects. In a previous study, only 
6 of the 11 subjects completed all of the four 100-min-long PET scans planned, possibly 
suggesting how hard it is to conduct crossover PET studies11).   
In summary, we examined H1RO of bepotastine at its recommended single oral 
dose (10 mg) and compared it to that of single oral administration of diphenhydramine (30 
mg) using PET measurement in a placebo-controlled crossover study.  Bepotastine 
occupied approximately 15% of available H1Rs in human brain while approximately 57% 
of H1Rs were occupied by 30 mg of diphenhydramine.  It is therefore suggested that oral 
administration of bepotastine (10 mg), with its low H1RO and thus minimal sedation, could 
safely be used an anti-allergic treatment for various allergic disorders.  It would be of a 
great benefit to estimate the appropriate therapeutic doses of new antihistamines and other 
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drugs using PET measurement and the smallest number of volunteers6-10).  Collection of 
more H1RO data is encouraged for establishment of a reliable international database for 
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Figure 1.  Mean brain images of healthy volunteers after administration of placebo, 
bepotastine and diphenhydramine. 
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